文献速递慢性肾脏病肾血管病与高血压

降压目标试验中估算肾小球滤过率急性下降与不良结局风险

Acute Declines in Estimated GFR in Blood Pressure Target Trials and Risk of Adverse Outcomes.
PubMed 文献 · Am J Kidney Dis · 2023-06-01

该回顾性观察研究纳入4项强化降压随机对照试验的4473例慢性肾脏病患者,分析估算肾小球滤过率急性下降(>15% vs ≤15%)与肾脏替代治疗风险的关系。中位随访22-24个月,强化降压组eGFR下降>15%者肾脏结局风险升高(HR 1.99),而eGFR下降≤15%者肾脏结局风险低于常规降压组(HR 0.75)。

要点

  • 强化降压组eGFR下降>15%者肾脏结局风险较常规降压组eGFR下降≤15%者升高(HR 1.99)。
  • 常规降压组eGFR下降>15%者肾脏结局风险亦升高(HR 2.47)。
  • 强化降压组eGFR下降≤15%者肾脏结局风险低于常规降压组eGFR下降≤15%者(HR 0.75)。

核心结论

  • 常规和强化降压组中eGFR下降>15%均与肾脏结局风险升高相关,可能是不良结局的前兆。

研究设计与样本

  • 回顾性观察研究,纳入4项强化降压随机对照试验(MDRD、AASK、SPRINT、ACCORD)的4473例慢性肾脏病患者。

主要发现

  • 中位随访22个月和24个月期间,分别发生351例肾脏结局和304例死亡。
  • eGFR急性下降总体发生率约14%,常规降压组为11.0%,强化降压组为17.8%。
  • 与常规降压组eGFR下降≤15%相比,强化降压组eGFR下降≤15%者肾脏结局风险降低(HR 0.75;95%CI 0.57-0.98)。
  • 与常规降压组eGFR下降≤15%相比,常规降压组eGFR下降>15%者肾脏结局风险升高(HR 2.47;95%CI 1.80-3.38)。
  • 与常规降压组eGFR下降≤15%相比,强化降压组eGFR下降>15%者肾脏结局风险升高(HR 1.99;95%CI 1.45-2.73)。

关键数值与推荐

  • eGFR急性下降定义为基线至第4个月eGFR变化>15%或≤15%。
  • 主要结局为肾脏替代治疗(透析或移植),ACCORD试验定义为血清肌酐>3.3mg/dL、肾衰竭或肾脏替代治疗的复合终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 观察性研究。
  • 残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Acute decreases in glomerular filtration rate (GFR) occur commonly during intensive blood pressure (BP) lowering. Our objective was to determine the relationship between acute decreases in estimated GFR and patient outcomes. STUDY DESIGN: Retrospective observational study. SETTING & PARTICIPANTS: Participants from 4 randomized controlled trials of intensive BP lowering in chronic kidney disease (Modification of Diet in Renal Disease study, African American Study of Kidney Disease and Hypertension, Systolic Blood Pressure Intervention Trial, and Action to Control Cardiovascular Risk in Diabetes trial). EXPOSURE: A 4-category exposure defined by the level of acute decrease in estimated GFR (defined as>15% vs≤15% between baseline and month 4) and the randomization to intensive versus usual BP control. OUTCOMES: Risk of kidney replacement therapy (primary outcome), defined as the need for dialysis or transplant except in the Action to Control Cardiovascular Risk in Diabetes trial, which defined its kidney outcome as a composite occurrence of serum creatinine concentration>3.3mg/dL, kidney failure, or kidney replacement therapy. ANALYTICAL APPROACH: Multivariable Cox models. RESULTS: We included 4,473 individuals randomly assigned to intensive versus usual BP control who had a total of 351 kidney outcomes and 304 deaths during median follow-up durations of 22 and 24 months, respectively. Approximately 14% of participants exhibited an acute decrease in eGFR, 11.0% in the usual BP treatment arm and 17.8% in the intensive BP treatment arm. In adjusted models, compared with a≤15% eGFR decrease in the usual BP arm, a≤15% eGFR decrease in the intensive BP control arm was associated with lower risk of the kidney outcome (HR, 0.75; 95% CI, 0.57-0.98). In contrast, a>15% decrease in eGFR was associated with a higher risk of the kidney outcome in the usual (HR, 2.47; 95% CI, 1.80-3.38) and intensive BP treatment arms (HR, 1.99; 95% CI, 1.45-2.73) compared with a≤15% decrease in the usual BP arm. LIMITATIONS: Observational study, residual confounding. CONCLUSIONS: Decreases in eGFR of>15% in the usual and intensive BP treatment arms were associated with a higher risk of kidney outcomes compared with a≤15% decrease in the usual BP arm and may be a harbinger of adverse outcomes.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Ku E, McCulloch CE, Copeland TP, et al. Acute Declines in Estimated GFR in Blood Pressure Target Trials and Risk of Adverse Outcomes. Am J Kidney Dis. 2023. PMID: 37269972. doi:10.1053/j.ajkd.2023.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。